secwatch.observer — SEC 8-K summary
======================================

Issuer:     Advanced Biomed Inc. (ADVB)
CIK:        0001941029
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001213900-26-051028
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Advanced Biomed completes AI pivot with acquisition of Acellent Technologies
----------------------------------------------------------------------------

- Acquired 100% of Acellent Technologies (HK) for 270,000 shares at $4/share, valued at $1.08M; closed April 30, 2026.
- Strategic pivot from life sciences to AI development; CEO Yi Lu mutually separated, receives 39,999 shares as severance.
- Xiaomin Chen appointed CEO, director, and chairman effective April 28; he has 20+ years AI experience including Google.
- Chen's base salary set at $12,000/month; eligible for bonuses and equity incentives.
- Chen is the sole shareholder of the acquired entity, creating a direct material interest in the transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/0001213900-26-051028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1941029/000121390026051028/ea0288766-8k_advanced.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-051028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer